ANAB
HEALTHCAREAnaptysBio Inc
AI Insight
What's Moving ANAB Today?
No stock-specific AI insight has been generated for ANAB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$11.40$72.36
$59.32
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-1.02
Dividend Yield—
Dividend / Share—
ROE-114.5%
Profit Margin-11.5%
Debt / Equity—
Trading
Volume132K
Avg Volume (10D)—
Shares Outstanding29.1M
ANAB News
24 articles- AnaptysBio (NASDAQ: ANAB) subleases San Diego facility to First Tracks under master leaseStock Titan·Jun 23, 2026
- ANAB proposes sale of 15,000 shares (NASDAQ: ANAB)Stock Titan·May 30, 2026
- [144] ANAPTYSBIO, INC SEC FilingStock Titan·May 22, 2026
- Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?Yahoo Finance·May 21, 2026
- Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?Yahoo Finance·May 19, 2026
- How The Grupo Traxión (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst TargetsYahoo Finance·May 15, 2026
- AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowYahoo Finance·May 14, 2026
- Anaptys Announces First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 12, 2026
- RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in FocusYahoo Finance·May 11, 2026
- Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of DirectorsYahoo Finance·May 11, 2026
- Assessing AnaptysBio (ANAB) Valuation After Royalty Pivot Spinoff And Legal OutcomeYahoo Finance·May 11, 2026
- Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?Yahoo Finance·May 10, 2026
- Why These Four Biotech Stocks Prove That Follow-On Entries Still Pop Up In Stock Market LeadersYahoo Finance·May 8, 2026
- TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 ViewYahoo Finance·May 7, 2026
- Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View RaisedYahoo Finance·May 7, 2026
- AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?Yahoo Finance·May 6, 2026
- Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?Yahoo Finance·May 5, 2026
- Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual ConferenceYahoo Finance·May 4, 2026
- AnaptysBio (ANAB) Is Up 13.4% After Court Upholds Jemperli Royalty Rights In Tesaro DisputeYahoo Finance·May 4, 2026
- Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM EvidenceYahoo Finance·Apr 28, 2026
- AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseYahoo Finance·Apr 27, 2026
- AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?Yahoo Finance·Apr 27, 2026
- GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBioProactive Investors·Apr 27, 2026
- Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach ClaimGlobeNewswire Inc.·Apr 24, 2026
All 24 articles loaded
Price Data
Open$58.31
Previous Close$59.43
Day High$60.51
Day Low$58.31
52 Week High$72.36
52 Week Low$11.40
52-Week Range
$11.40$72.36
$59.32
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-1.02
Dividend Yield—
Dividend / Share—
ROE-114.5%
Profit Margin-11.5%
Debt / Equity—
Trading
Volume132K
Avg Volume (10D)—
Shares Outstanding29.1M
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—